US EditionPublished • loading... • Updated
Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension
Summary by Intelligence360 News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension
– Follows successful completion of pre-clinical activities by Alchemab as part of earlier licensing deal with Eli Lilly and Company for ATLX-1282 – Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors CAMBRIDGE, England, Sept. 9, 2025 /PRNewswire/ — Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops nat…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
